168 related articles for article (PubMed ID: 28575121)
1. Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats.
Leshinsky J; McLachlan A; Foster DJR; Norris R; Barrs VR
PLoS One; 2017; 12(6):e0178783. PubMed ID: 28575121
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.
Wiederhold NP; Kontoyiannis DP; Chi J; Prince RA; Tam VH; Lewis RE
J Infect Dis; 2004 Oct; 190(8):1464-71. PubMed ID: 15378439
[TBL] [Abstract][Full Text] [Related]
3. Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration.
Pérez-Pitarch A; Ferriols-Lisart R; Aguilar G; Ezquer-Garín C; Belda FJ; Guglieri-López B
Int J Antimicrob Agents; 2018 Jan; 51(1):115-121. PubMed ID: 28666752
[TBL] [Abstract][Full Text] [Related]
4. Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction.
van der Elst KC; Brüggemann RJ; Rodgers MG; Alffenaar JW
Transpl Infect Dis; 2012 Aug; 14(4):440-3. PubMed ID: 22316392
[TBL] [Abstract][Full Text] [Related]
5. Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis.
van de Sande WW; van Vianen W; ten Kate MT; Vissers J; Laurijsens J; Tavakol M; Rijnders BJ; Mathot RA; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 2008 Apr; 52(4):1345-50. PubMed ID: 18195059
[TBL] [Abstract][Full Text] [Related]
6. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
[TBL] [Abstract][Full Text] [Related]
7. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants.
Migoya EM; Mistry GC; Stone JA; Comisar W; Sun P; Norcross A; Bi S; Winchell GA; Ghosh K; Uemera N; Deutsch PJ; Wagner JA
J Clin Pharmacol; 2011 Feb; 51(2):202-11. PubMed ID: 20679501
[TBL] [Abstract][Full Text] [Related]
9. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
[TBL] [Abstract][Full Text] [Related]
10. Phase II dose escalation study of caspofungin for invasive Aspergillosis.
Cornely OA; Vehreschild JJ; Vehreschild MJ; Würthwein G; Arenz D; Schwartz S; Heussel CP; Silling G; Mahne M; Franklin J; Harnischmacher U; Wilkens A; Farowski F; Karthaus M; Lehrnbecher T; Ullmann AJ; Hallek M; Groll AH
Antimicrob Agents Chemother; 2011 Dec; 55(12):5798-803. PubMed ID: 21911573
[TBL] [Abstract][Full Text] [Related]
11. Low Caspofungin Exposure in Patients in Intensive Care Units.
van der Elst KC; Veringa A; Zijlstra JG; Beishuizen A; Klont R; Brummelhuis-Visser P; Uges DR; Touw DJ; Kosterink JG; van der Werf TS; Alffenaar JC
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855112
[TBL] [Abstract][Full Text] [Related]
12. Fungicidal activity and PK/PD of caspofungin as tools to guide antifungal therapy in a fluconazole-resistant C. parapsilosis candidemia.
Tascini C; Sozio E; Di Paolo A; Tintori G; Leonildi A; Bertolino G; Carmassi F; Tagliaferri E; Menichetti F; Barchiesi F
J Chemother; 2017 Dec; 29(6):376-379. PubMed ID: 28198656
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of caspofungin in ICU patients.
Muilwijk EW; Schouten JA; van Leeuwen HJ; van Zanten AR; de Lange DW; Colbers A; Verweij PE; Burger DM; Pickkers P; Brüggemann RJ
J Antimicrob Chemother; 2014 Dec; 69(12):3294-9. PubMed ID: 25139840
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus.
Lewis RE; Liao G; Hou J; Prince RA; Kontoyiannis DP
J Antimicrob Chemother; 2011 Jun; 66(6):1324-31. PubMed ID: 21486855
[TBL] [Abstract][Full Text] [Related]
15. Caspofungin acetate for treatment of invasive fungal infections.
Pacetti SA; Gelone SP
Ann Pharmacother; 2003 Jan; 37(1):90-8. PubMed ID: 12503942
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis.
Würthwein G; Cornely OA; Trame MN; Vehreschild JJ; Vehreschild MJ; Farowski F; Müller C; Boos J; Hempel G; Hallek M; Groll AH
Antimicrob Agents Chemother; 2013 Apr; 57(4):1664-71. PubMed ID: 23335740
[TBL] [Abstract][Full Text] [Related]
17. Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.
Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Brüggemann RJ; Lefrant JY; Roberts JA
Clin Pharmacokinet; 2017 Sep; 56(9):1057-1068. PubMed ID: 28035589
[TBL] [Abstract][Full Text] [Related]
18. Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.
Martial LC; Brüggemann RJ; Schouten JA; van Leeuwen HJ; van Zanten AR; de Lange DW; Muilwijk EW; Verweij PE; Burger DM; Aarnoutse RE; Pickkers P; Dorlo TP
Clin Pharmacokinet; 2016 Jun; 55(6):723-33. PubMed ID: 26649870
[TBL] [Abstract][Full Text] [Related]
19. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.
Stone JA; Holland SD; Wickersham PJ; Sterrett A; Schwartz M; Bonfiglio C; Hesney M; Winchell GA; Deutsch PJ; Greenberg H; Hunt TL; Waldman SA
Antimicrob Agents Chemother; 2002 Mar; 46(3):739-45. PubMed ID: 11850256
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, efficacy, and safety of caspofungin in Japanese pediatric patients with invasive candidiasis and invasive aspergillosis.
Mori M; Imaizumi M; Ishiwada N; Kaneko T; Goto H; Kato K; Hara J; Kosaka Y; Koike K; Kawamoto H; Maeda N; Yoshinari T; Kishino H; Takahashi K; Kawahara S; Kartsonis NA; Komada Y
J Infect Chemother; 2015 Jun; 21(6):421-6. PubMed ID: 25701307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
